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visceral metastasis were excluded from the study. All the patients 
were treated in two phases to a total dose of 5940cGy. Phase I CTV 
(treated to a dose of 45Gy in 25 fractions) was generated by 
expanding the GTV primary cranio-caudally by 4cm and laterally to 
include electively, the corresponding level mediastinal nodes. Phase II 
CTV was generated by expanding the GTV by 2cm craniocaudally and 
1cm radially. Bilateral supraclavicular regions were electively 
included for supracarinal lesions. ITV was generated by expanding the 
CTV by 0.5cm which was then expanded by 0.5cm to yield PTV. IG-RA 
plans consisted of 2 conformal arcs with a high priority to reduce lung 
V20, mean lung dose and heart dose. The set-up was verified by daily 
KV imaging as well as thrice weekly CBCT with oral barium. 
Chemotherapy consisted of 4-6 cycles of weekly cisplatin 40mg/m2. 
Results: The median age of patients was 53 yrs (43-72).The median 
length of involvement of esophagus was 6cm with 80% of the lesions in 
the upper and middle third. 37/41(90%) patients completed planned 
chemotherapy with atleast 4 cycles of cisplatin and 40/41 patients 
completed full dose of radiotherapy. 4/41 (10%) patients required 
tube feeding, 2/41 (5%)patients required hospital admission for 
supportive care but none of the patients had grade IV hematological 
toxicity during treatment. Endoscopy at 8 weeks post treatment was 
performed in 38/41 patients of whom 20 (53%) had CR,16 (42%) had PR 
and 2 (5%) had stable disease locally. With a median follow up of 15 
(6-20) months, 18/41(44%) patients are alive at last follow-up of which 
13 (32%) are disease free with no dysphagia, the 1 and 2 year overall 
survival are 70% and 42% respectively and median survival of 13.5 
months. 3/18 (16%)alive patients have post radiotherapy stricture 
requiring occasional dilatations. Unfortunately none of the patients 
underwent salvage surgery because of various medical and social 
reasons. After analyzing KV image datasets, the modal corrections 
applied for bone matching was 0.1cm (vertical),0.2cm (lateral and 
0.2cm longitudinal. The analysis of CBCT data sets showed that the 
ITV and PTV margins of 0.5cm each were found to be adequate with 
current imaging protocol. 
Conclusions: Image guided volumetric modulated arc therapy to a 
dose of 60Gy with concurrent weekly cisplatin is a feasible treatment 
option for locally advanced inoperable squamous cell carcinoma of 
thoracic esophagus with low acute and late toxicity and with 
promising early clinical outcomes. The ITV and PTV margins of 0.5cm 
were found to be adequate only with image guidance.  
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Purpose/Objective: VEGFR, EGFR, Cox-2 and p53 stimulates key 
processes involved in tumor growth, progression and proliferation, and 
are important targets for cancer therapeutics. Ki-67 is a marker of 
tumor activity.The prognostic and predictive value of these novel 
biomolecular markers expression in association with proliferation in 
selecting targeted agents is currently unknown.The purpose of this 
study was to measure co-expression of EGFR, VEGFR, Cox-2, p53 and 
Ki67 proteins in pre-treatment tumor biopsies of rectal cancer 
patients treated with neoadjuvant treatment and to correlate 
expression with clinical outcome. 
Materials and Methods: EGFR,VEGFR, Cox-2, p53 and Ki67 co-
expression was measured using immunohistochemistry quantitative 
image analysis. Ki67% activity (positive ≥90%) was quantified within 
EGFR, VEGFR, Cox-2 and p53 tumor in high versus low expression. Cox 
proportional hazards models were used to explore associations 
between the tumor markers and disease-free survival (DFS). 
Results: 38 pre-treatment tumors were analyzed. Patients median 
follow-up was 69.3 months (range,4.5-92). Onunivariate analysis, high 
Ki67% activity in VEGFR (HR 4.06 [1.14, 14.43], p =0.03), Cox-2 (HR 
3.89 [1.12, 13.45], p = 0.03); and p53 (HR 4.15 [1.07, 16.07], p Z 0.04) 
high expression tumors was associated with worse DFS. On 
multivariate analysis, only high Ki67% activity in VEGFR high 
expression tumors remained statistically significant forDFS (HR 4.07 
[1.14, 14.3], p = 0.04). 
Conclusions: High Ki67% activity in VEGFR high expression tumors are 
associated with worse DFS in patients with rectal cancer treated with 
induction CT followed by pelvic CRTand surgery. Determination of the 
optimal diagnostic cut-off level for this novel biomarker association 
should be explored. Evaluation within a clinical trial will be required 
to determine whether patients could benefit from an VEGFR targeted 
therapeutic agent. 
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Purpose/Objective: This study investigated the utility of deformable 
image registration in accurately assessing the pattern of local relapse 
with respect to the high dose treatment volume in patients with 
oesophageal cancer following chemoradiation. 
Materials and Methods: Data was collected for 15 patients treated 
between 2009 and 2010. Seven of these patients (46.7%) relapsed; two 
patients (13.3%) had infield recurrence and five (33.3%) experienced 
distant recurrence. All patients were treated with chemoradiation (as 
per the NCRI UK SCOPE trial protocol but not all treated witihin the 
trial) and received conformal radiotherapy of 50Gy in 25 fractions to 
the PTV. This PTV was derived from a CTV based on a CT scan with 
information from un-registered PET-CT and endoscopic ultrasound. 
Retrospectively, deformable image registration was performed 
(Mirada RTx, Mirada Medical, Oxford, UK) between the original 
planning CT and the PET-CT images. Tumour volumes were contoured 
on the PET-CT images and projected onto the original planning CT. In 
addition, for local relapse patients, deformable image registration 
was carried out between the planning CT and the relapse CT images. 
(Figure 1) The site of relapse was contoured and projected onto the 
planning CT. This enabled comparison of the site of relapse relative to 
the planning CT and PET-CT volumes and the dose received by each 
volume to evaluate tumour coverage. Dosimetric analysis was 
undertaken. (Table 1)  
Results: Deformable registration (not rigid body) was necessary to 
accurately transfer relapse CT derived contours to the planning CT as 
the patients typically had different curvature of the spine and 
oesophagus in the PET-CT and diagnostic relapse CT compared to 
planning CT. Of the two local relapses, one was within the PET-CT 
volume whilst the other was in the high dose penumbra (small cell 
oesophageal cancer). This patient died of distant metastatic disease. 
 










4 Patient 5 Patient 6 Patient 7 
GTV 49.99 50.24 49.54 50.24 49.65 50.30 48.86 
CTV or 
CTVa/CTVb48.53 n-a 49.37 49.24 49.58/49.24 48.83/48.99 47.19/47.47
PTV 48.13 49.84 n-a 48.70 48.30 47.03 42.94 
PET 




n-a 8.36 n-a n-a n-a n-a 47.45 
Figure 1: Deformable co-registered image of relapse CT and planning 
CT scan  
 
Black = Original Planning Target Volume 
White = Relapse region 
 
Conclusions: Deformable image registration is a valuable tool that 
allows relapse CT data to be compared accurately to the original 
planning CT and therefore determine if current target definition is 
adequate. Investigation of a larger cohort is required to confirm these 
observations by including this this procedure in the analysis of future 
